CA2212047C - Triglycerides and ethyl esters of phenylalkanoic acid and phenylalkenoic acid useful in treatment of various disorders - Google Patents

Triglycerides and ethyl esters of phenylalkanoic acid and phenylalkenoic acid useful in treatment of various disorders Download PDF

Info

Publication number
CA2212047C
CA2212047C CA2212047A CA2212047A CA2212047C CA 2212047 C CA2212047 C CA 2212047C CA 2212047 A CA2212047 A CA 2212047A CA 2212047 A CA2212047 A CA 2212047A CA 2212047 C CA2212047 C CA 2212047C
Authority
CA
Canada
Prior art keywords
even number
treatment
formula
compound
zero
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CA2212047A
Other languages
English (en)
French (fr)
Other versions
CA2212047A1 (en
Inventor
Saul W. Brusilow
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Brusilow Enterprises LLC
Original Assignee
Brusilow Enterprises LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23519346&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CA2212047(C) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Brusilow Enterprises LLC filed Critical Brusilow Enterprises LLC
Publication of CA2212047A1 publication Critical patent/CA2212047A1/en
Application granted granted Critical
Publication of CA2212047C publication Critical patent/CA2212047C/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C57/00—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
    • C07C57/30—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms containing six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/612—Esters of carboxylic acids having a carboxyl group bound to an acyclic carbon atom and having a six-membered aromatic ring in the acid moiety
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/612—Esters of carboxylic acids having a carboxyl group bound to an acyclic carbon atom and having a six-membered aromatic ring in the acid moiety
    • C07C69/618—Esters of carboxylic acids having a carboxyl group bound to an acyclic carbon atom and having a six-membered aromatic ring in the acid moiety having unsaturation outside the six-membered aromatic ring

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CA2212047A 1995-02-07 1996-02-06 Triglycerides and ethyl esters of phenylalkanoic acid and phenylalkenoic acid useful in treatment of various disorders Expired - Fee Related CA2212047C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US384,935 1982-06-04
US38493595A 1995-02-07 1995-02-07
PCT/US1996/000940 WO1996024571A1 (en) 1995-02-07 1996-02-06 Triglycerides and ethyl esters of phenylalkanoic acid and phenylalkenoic acid useful in treatment of various disorders

Publications (2)

Publication Number Publication Date
CA2212047A1 CA2212047A1 (en) 1996-08-15
CA2212047C true CA2212047C (en) 2010-11-16

Family

ID=23519346

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2212047A Expired - Fee Related CA2212047C (en) 1995-02-07 1996-02-06 Triglycerides and ethyl esters of phenylalkanoic acid and phenylalkenoic acid useful in treatment of various disorders

Country Status (9)

Country Link
US (3) US5968979A (cg-RX-API-DMAC7.html)
EP (1) EP0858441B1 (cg-RX-API-DMAC7.html)
AT (1) ATE201013T1 (cg-RX-API-DMAC7.html)
AU (1) AU4858796A (cg-RX-API-DMAC7.html)
CA (1) CA2212047C (cg-RX-API-DMAC7.html)
DE (1) DE69612755T2 (cg-RX-API-DMAC7.html)
ES (1) ES2157422T3 (cg-RX-API-DMAC7.html)
FR (1) FR16C0003I2 (cg-RX-API-DMAC7.html)
WO (1) WO1996024571A1 (cg-RX-API-DMAC7.html)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6642543B1 (en) 2000-09-26 2003-11-04 The Board Of Trustees Of The Leland Stanford Junior University Thin and thick gate oxide transistors on a functional block of a CMOS circuit residing within the core of an IC chip
US7842727B2 (en) 2001-03-27 2010-11-30 Errant Gene Therapeutics, Llc Histone deacetylase inhibitors
US6495719B2 (en) * 2001-03-27 2002-12-17 Circagen Pharmaceutical Histone deacetylase inhibitors
US8026280B2 (en) 2001-03-27 2011-09-27 Errant Gene Therapeutics, Llc Histone deacetylase inhibitors
US7312247B2 (en) * 2001-03-27 2007-12-25 Errant Gene Therapeutics, Llc Histone deacetylase inhibitors
US20030195255A1 (en) * 2002-04-12 2003-10-16 Summar Marshall L. Method for treating hepatic encephalopathies
US20040229948A1 (en) * 2002-04-12 2004-11-18 Summar Marshall L. Method for preventing hepatic encephalopathic episodes
EP1511477A4 (en) 2002-05-22 2008-04-09 Errant Gene Therapeutics Llc HISTONE DEACETYLASE INHIBITORS BASED ON ALPHA-KETO-EPOXYDE COMPOUNDS
JP2006508986A (ja) * 2002-11-20 2006-03-16 エルラント ゲネ セラペウチクス エルエルシー ヒストンデアセチラーゼ阻害剤による肺細胞の治療方法
US20090260743A1 (en) * 2003-11-21 2009-10-22 William David Mawby Tire manufacturing method for improving the uniformity of a tire
CA2587013A1 (en) * 2004-11-08 2006-05-18 Errant Gene Therapeutics, Llc Histone deacetylase inhibitors
WO2009134460A1 (en) * 2008-04-29 2009-11-05 Hyperion Therapeutics Methods of treatment using ammonia-scavenging drugs
JP5577341B2 (ja) * 2008-08-29 2014-08-20 ハイペリオン セラピューティクス, インコーポレイテッド アンモニア捕捉薬を使用する処置方法
EP3263102A1 (en) 2011-09-30 2018-01-03 Horizon Therapeutics, LLC Methods of therapeutic monitoring of nitrogen scavenging drugs
BR112014026138A2 (pt) 2012-04-20 2017-06-27 Hyperion Therapeutics Inc métodos de monitoramento terapêutico de pró-fármacos de ácido fenilacético
HUE036133T2 (hu) * 2012-11-21 2018-06-28 Horizon Therapeutics Llc Eljárások hepatikus enkefalopátia kezelésére szolgáló nitrogénelvonó gyógyszerek beadására és értékelésére
PL2986325T3 (pl) 2013-10-14 2020-03-31 Immedica Pharma Ab Sposoby leczenia zaburzenia cyklu mocznikowego
IN2013MU03442A (cg-RX-API-DMAC7.html) 2013-10-30 2015-07-17 Lupin Ltd
JP2017501972A (ja) 2013-11-14 2017-01-19 ウルトラジェニクス ファーマシューティカル インク.Ultragenyx Pharmaceutical Inc. トリグリセリドの固体組成物及びその使用
EP3137116B1 (en) 2014-04-30 2020-12-16 The Johns Hopkins University Dendrimer compositions and their use in treatment of diseases of the eye
EP3180031A1 (en) 2014-08-13 2017-06-21 The Johns Hopkins University Selective dendrimer delivery to brain tumors
CN108430514B (zh) 2015-10-29 2023-11-03 约翰霍普金斯大学 用于治疗过氧化物酶体病症和脑白质营养不良的组合物和方法
US9914692B2 (en) 2016-05-25 2018-03-13 Horizon Therapeutics, Llc Procedure for the preparation of 4-phenyl butyrate and uses thereof
US10668040B2 (en) 2017-09-11 2020-06-02 Horizon Therapeutics, Llc Treatment of urea cycle disorders in neonates and infants
WO2021113662A2 (en) 2019-12-04 2021-06-10 Ashvattha Therapeutics, Inc. Dendrimer compositions and methods for drug delivery to the eye

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5879657A (en) * 1993-03-30 1999-03-09 The Dupont Merck Pharmaceutical Company Radiolabeled platelet GPIIb/IIIa receptor antagonists as imaging agents for the diagnosis of thromboembolic disorders

Also Published As

Publication number Publication date
EP0858441B1 (en) 2001-05-09
WO1996024571A1 (en) 1996-08-15
US6060510A (en) 2000-05-09
EP0858441A4 (cg-RX-API-DMAC7.html) 1998-08-19
FR16C0003I1 (cg-RX-API-DMAC7.html) 2016-03-25
US6083984A (en) 2000-07-04
FR16C0003I2 (fr) 2016-06-24
AU4858796A (en) 1996-08-27
CA2212047A1 (en) 1996-08-15
EP0858441A1 (en) 1998-08-19
ES2157422T3 (es) 2001-08-16
DE69612755D1 (de) 2001-06-13
DE69612755T2 (de) 2001-08-23
US5968979A (en) 1999-10-19
ATE201013T1 (de) 2001-05-15

Similar Documents

Publication Publication Date Title
EP0858441B1 (en) Triglycerides and ethyl esters of phenylalkanoic acid and phenylalkenoic acid useful in treatment of various disorders
Newmark et al. Butyrate and phenylacetate as differentiating agents: practical problems and opportunities
EP0085579B1 (en) Topical pharmaceutical compositions
US5709855A (en) Compositions of spirulina algae and omega fatty acids for treatment of inflammation and pain
ES2576578T3 (es) Composición de ácidos grasos n-3 que presentan una concentración elevada de EPA y/o DHA y que contiene ácidos grasos n-6
US6046237A (en) Non-β-oxidizable fatty acid analogues, their uses as therapeutic active medicaments
JP2001526663A (ja) ピルビン酸塩の医療的使用
US5569680A (en) Method of treating inflammatory bowel disease with tributyrin
EP0177499A1 (en) Process for waste nitrogen removal
US5763488A (en) Methods and compositions using butyrate esters of threitol
US5645852A (en) Butyric ester cyto-differtiating agents
CA2024724A1 (en) Fatty acid therapy
US11066423B2 (en) Monomeric bimetal hydroxycitric acid compounds and methods of making and using the same
US20020115716A1 (en) Oral low dose butyrate compositions
EP0637449B1 (en) Use of L-carnitine or acyl L-carnitines and valproate for treating seizure disorders
CA2456144A1 (en) A group of novel anti-cancer compounds with specific structure
EP1058545A1 (en) Cancer management with tamoxifen and gammalinolenic acid
CA1221636A (en) Process for waste nitrogen removal
BOCCARDO et al. Phase II Evaluation of 4-Thiazolidine-Carboxylic Acid
CA2235603A1 (en) Methods and compositions using butyrate esters of threitol
HK1005771B (en) Use of l-carnitine or acyl l-carnitines and valproate for treating seizure disorders

Legal Events

Date Code Title Description
EEER Examination request
FZDC Discontinued application reinstated
MKLA Lapsed

Effective date: 20160208